Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60

Zura Bio Limited (NASDAQ:ZURA) has been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $11.40.

Several research firms have recently weighed in on ZURA. Wedbush assumed coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 target price on the stock. Oppenheimer reduced their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Leerink Partners raised Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd.

Insider Transactions at Zura Bio

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The stock was purchased at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the transaction, the insider owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atika Capital Management LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth $1,195,000. Suvretta Capital Management LLC increased its position in Zura Bio by 12.6% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock valued at $23,698,000 after buying an additional 611,952 shares in the last quarter. Savant Capital LLC increased its position in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after buying an additional 21,249 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in Zura Bio in the third quarter valued at about $3,568,000. Finally, Forefront Wealth Partners LLC acquired a new stake in Zura Bio in the third quarter worth about $93,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Down 10.1%

Zura Bio stock opened at $5.50 on Friday. Zura Bio has a 52-week low of $0.97 and a 52-week high of $7.44. The firm’s fifty day moving average is $6.17 and its 200 day moving average is $4.57. The company has a market cap of $357.61 million, a price-to-earnings ratio of -5.19 and a beta of 0.18.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). On average, equities research analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.